Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 3/20 | 0.58 |
| ▸ | ACHE | P22303 | 3/20 | 0.58 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.56 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.56 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.49 |
| ▸ | IDO1 | P14902 | 2/20 | 0.49 |
| ▸ | AGXT | P21549 | 2/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27419663 | 0.89 | ACHE (0.64) | BCHEACHECALM1CAMKK2AOC3 | |
| SCHEMBL15790970 | 0.89 | BCHE (0.56) | BCHEACHECALM1CAMKK2AOC3 | |
| SCHEMBL1134084 | 0.88 | KMT2A (0.61) | BCHEACHECALM1CAMKK2AOC3 | |
| SCHEMBL4526554 | 0.86 | CALM1 (0.55) | BCHEACHECALM1CAMKK2AOC3 | |
| SCHEMBL12992872 | 0.85 | BCHE (0.60) | BCHEACHECALM1CAMKK2AOC3 | |
| SCHEMBL30093216 | 0.84 | CALM1 (0.60) | BCHEACHECALM1CAMKK2AOC3 | |
| SCHEMBL18714774 | 0.83 | CHRM2 (0.62) | BCHEACHECALM1CAMKK2AOC3 | |
| SCHEMBL23507393 | 0.82 | GRIN2D (0.51) | BCHEACHECALM1TSHRALDH1A1 | |
| SCHEMBL9416597 | 0.81 | ACHE (0.59) | BCHEACHECALM1CAMKK2AOC3 | |
| SCHEMBL850832 | 0.80 | CALM1 (0.64) | BCHEACHECALM1CAMKK2AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9765091-B2 | Tetrahydropyrazolo [3,4-b] azepine derivatives and their use as allosteric modulators of metabotropic glutamate receptors | ADDEX PHARMA S.A. (CH) | 2017-09-19 | — | — | US | disclosed |
| US-20130267499-A1 | NOVEL TETRAHYDROPYRAZOLO [3,4-b] AZEPINE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2013-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267499-A1 | NOVEL TETRAHYDROPYRAZOLO [3,4-b] AZEPINE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM4, GRM1, GRIK4 | BCHE 669/4885ACHE 839/4885CALM1 1254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.